TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance

Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Te...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 1071390
Main Authors Liu, Tiantian, Li, Shihong, Xia, Chuanyou, Xu, Dawei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.01.2023
Subjects
BCG
Carcinoma, Transitional Cell - genetics
Clinical Relevance
Humans
Immunology
immunotherapy
Methylation
Mutation
promoter methylation
promoter mutations
telomerase
Telomerase - genetics
Telomerase - metabolism
TERT
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - pathology
telomerase
urothelial carcinoma
TERT
promoter methylation
urothelial cells
BCG
immunotherapy
promoter mutations
Online AccessGet full text

Cover

Abstract Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT) , a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.
AbstractList Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT), a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT), a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.
Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the , a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.
Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT) , a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.
Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely activated in urothelial cell-derived carcinomas or urothelial carcinomas (UCs) including UC of the bladder (UCB) and upper track UC (UTUC). Telomerase activation for telomere maintenance is required for the UC development and progression, and the key underlying mechanism is the transcriptional de-repression of the telomerase reverse transcriptase (TERT), a gene encoding the rate-limiting, telomerase catalytic component. Recent mechanistic explorations have revealed important roles for TERT promoter mutations and aberrant methylation in activation of TERT transcription and telomerase in UCs. Moreover, these TERT-featured genomic and epigenetic alterations have been evaluated for their usefulness in non-invasive UC diagnostics, recurrence monitoring, outcome prediction and response to treatments such as immunotherapy. Importantly, the detection of the mutated TERT promoter and TERT mRNA as urinary biomarkers holds great promise for urine-based UC liquid biopsy. In the present article, we review recent mechanistic insights into altered TERT promoter-mediated telomerase activation in UCs and discuss potential clinical implications. Specifically, we compare differences in senescence and transformation between NHUCs and other types of epithelial cells, address the interaction between TERT promoter mutations and other factors to affect UC progression and outcomes, evaluate the impact of TERT promoter mutations and TERT-mediated activation of human endogenous retrovirus genes on UC immunotherapy including Bacillus Calmette-Guérin therapy and immune checkpoint inhibitors. Finally, we suggest the standardization of a TERT assay and evaluation system for UC clinical practice.
Author Liu, Tiantian
Li, Shihong
Xia, Chuanyou
Xu, Dawei
AuthorAffiliation 2 Department of Pathology, Maternal and Child Health Hospital of Liaocheng , Liaocheng , China
1 Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University , Jinan , China
4 Department of Medicine, Bioclinicum and Center for Molecular Medicine (CMM), Karolinska Institutet and Karolinska University Hospital Solna , Stockholm , Sweden
3 Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital , Jinan , China
AuthorAffiliation_xml – name: 2 Department of Pathology, Maternal and Child Health Hospital of Liaocheng , Liaocheng , China
– name: 3 Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital , Jinan , China
– name: 4 Department of Medicine, Bioclinicum and Center for Molecular Medicine (CMM), Karolinska Institutet and Karolinska University Hospital Solna , Stockholm , Sweden
– name: 1 Department of Pathology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University , Jinan , China
Author_xml – sequence: 1
  givenname: Tiantian
  surname: Liu
  fullname: Liu, Tiantian
– sequence: 2
  givenname: Shihong
  surname: Li
  fullname: Li, Shihong
– sequence: 3
  givenname: Chuanyou
  surname: Xia
  fullname: Xia, Chuanyou
– sequence: 4
  givenname: Dawei
  surname: Xu
  fullname: Xu, Dawei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36713366$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:151738428$$DView record from Swedish Publication Index
BookMark eNp9ksFu1DAQhiNUREvpC3BAOXLZJc44tsMBCVUFKlUgoeVsOc5k18WxF9tp1ZfgmfFulqrLAV88mvn_b2zpf1mcOO-wKF6Tagkg2neDGcdpWVd1vSQVJ9BWz4ozwhhdQF3Tkyf1aXER422VD20BoHlRnALLDmDsrPi9uvq-KrfBjz5hKMcpqWS8i6VyfTli2jzYfaMcfCgTWj9iUBFLpZO5myfGlVPwaYPWKFtqFbRxflTxffkV7zNDb5QzMRmdldGsN2mGa2uc0dmRe84MuXQaXxXPB2UjXhzu8-LHp6vV5ZfFzbfP15cfbxa6qVhacBAEesUHVKxTXBPRccFAA2iCXOuuG1gHokHQQrV1A0KQhlV0UITzrgc4L65nbu_VrdwGM6rwIL0yct_wYS1VyE-2KNsBKhiQY0sqqqkSPfQZzpiipKeAmbWYWfEet1N3RDu0fuYKJaUiI7L-w6zPkxF7jS4FZY9sxxNnNnLt72QrOAeyA7w9AIL_NWFMcjRRo7XKoZ-irDknVf4x3f3zzdNdj0v-BiAL6lmgg48x4PAoIZXcBU3ugyZ3QZOHoGWT-MekzZyb_F5j_2f9A4ZW3ks
CitedBy_id crossref_primary_10_1186_s40164_025_00597_9
crossref_primary_10_3389_fimmu_2023_1208223
crossref_primary_10_1016_j_jbc_2024_107994
crossref_primary_10_3389_fimmu_2023_1126247
crossref_primary_10_1158_2767_9764_CRC_24_0569
crossref_primary_10_1590_1516_3180_2023_0140_r1_04032024
crossref_primary_10_1038_s41378_023_00581_5
crossref_primary_10_3390_genes15111424
crossref_primary_10_1186_s13578_023_01181_6
crossref_primary_10_3390_ijms25115660
crossref_primary_10_1186_s12885_024_12913_3
crossref_primary_10_3389_fgene_2024_1401100
Cites_doi 10.1002/ijc.31935
10.1016/j.molcel.2007.09.023
10.1016/j.eururo.2013.08.052
10.1038/s41568-021-00335-3
10.3390/cancers14184384
10.1016/j.juro.2016.09.118
10.1016/j.urolonc.2009.01.003
10.1101/gad.12.2.163
10.1002/hep.27372
10.3390/genes12020230
10.1371/journal.pbio.2000016
10.1172/JCI91161
10.1158/0008-5472.CAN-13-2498
10.1016/j.eururo.2016.12.008
10.1016/j.eururo.2016.06.035
10.7150/jca.56779
10.1038/s41467-021-23221-w
10.3389/fimmu.2022.963877
10.3389/fonc.2020.597486
10.1038/sj.onc.1207260
10.18632/oncotarget.11883
10.1016/j.euf.2017.07.004
10.1016/S0022-5347(05)65281-0
10.1038/sj.onc.1209513
10.1016/j.ccell.2021.05.008
10.1111/his.12920
10.1136/jitc-2021-004345
10.3390/cancers12123541
10.1038/nature12965
10.2174/1568026620666200106145340
10.1016/j.cell.2011.02.013
10.15252/embr.202152984
10.1210/clinem/dgaa182
10.1016/j.eururo.2013.08.057
10.1038/s41556-020-0471-6
10.1016/j.urolonc.2021.01.022
10.1002/1878-0261.13324
10.1016/j.anndiagpath.2015.12.002
10.18632/oncotarget.15498
10.1016/j.cell.2015.07.011
10.1038/s41418-019-0466-7
10.1002/gcc.20672
10.1111/his.13441
10.3389/fgene.2016.00083
10.1016/S0002-9440(10)65025-0
10.1038/onc.2013.446
10.18632/oncotarget.1829
10.1097/JU.0000000000000786
10.1016/j.humpath.2022.06.005
10.3233/BLC-170152
10.1158/1541-7786.MCR-07-2168
10.1038/nrurol.2017.11
10.1186/s12967-018-1456-0
10.1172/JCI121476
10.1002/cncr.28800
10.1126/science.aab0015
10.3389/fimmu.2020.589929
10.1002/ijc.29526
10.1126/science.1229259
10.1073/pnas.93.24.13742
10.3389/fimmu.2021.663865
10.1111/cas.14000
10.1038/oncsis.2015.39
10.1016/j.canlet.2020.07.003
10.1016/j.ccell.2018.08.003
10.1186/s13059-021-02357-4
10.1016/j.urolonc.2020.05.012
10.1128/MCB.22.14.5157-5172.2002
10.1186/s13046-022-02382-6
10.1136/jitc-2020-002127
10.1016/j.cell.2018.05.052
10.1126/science.279.5349.349
10.1016/j.urolonc.2019.08.007
10.1016/j.prp.2022.153983
10.1002/bco2.147
10.18632/oncotarget.4295
10.1002/1878-0261.12746
10.1634/theoncologist.2014-0391
10.1038/s41586-021-03994-2
10.1038/bjc.2017.210
10.1038/s41388-018-0483-x
10.1186/s12967-022-03624-z
10.3389/fimmu.2021.682492
10.1155/2012/693631
10.1016/j.celrep.2017.12.001
10.3390/ncrna4010001
10.3389/fonc.2021.705440
10.1073/pnas.94.25.13677
10.1186/s40169-020-0257-2
10.1080/21655979.2021.1915725
10.1002/ctm2.1111
10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1
10.1016/j.eururo.2013.10.038
10.1002/ijc.21168
10.1073/pnas.1310522110
10.3390/cancers14061385
10.1007/s00432-009-0557-9
10.1038/s41388-019-0872-9
10.1016/j.eururo.2011.02.022
10.1016/S0959-8049(97)00062-2
10.18632/oncotarget.2660
10.1002/1878-0261.12786
10.1073/pnas.2102423118
10.1038/s41576-019-0099-1
10.3390/ijms21030947
10.1016/j.clinbiochem.2018.11.009
10.1056/NEJMoa1502583
10.3390/cancers14143537
10.1038/23962
10.1016/j.molcel.2021.03.033
10.1007/978-981-13-2835-0_9
10.1016/j.juro.2007.03.025
10.1155/2021/5552614
10.4161/cc.24662
10.1126/science.1230062
10.1038/ng.3781
10.1016/j.ebiom.2020.102643
10.3389/fgene.2019.01237
10.1097/PAS.0000000000000305
10.1038/onc.2012.441
10.1158/0008-5472.CAN-16-1887
ContentType Journal Article
Copyright Copyright © 2023 Liu, Li, Xia and Xu.
Copyright © 2023 Liu, Li, Xia and Xu 2023 Liu, Li, Xia and Xu
Copyright_xml – notice: Copyright © 2023 Liu, Li, Xia and Xu.
– notice: Copyright © 2023 Liu, Li, Xia and Xu 2023 Liu, Li, Xia and Xu
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
DOA
DOI 10.3389/fimmu.2022.1071390
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Freely available online
SwePub Articles full text
Open Access资源_DOAJ
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals (WRLC)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_9f303fe7e9104c4a8d3d6b366a41d43e
oai_swepub_ki_se_448104
PMC9877314
36713366
10_3389_fimmu_2022_1071390
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: ;
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ADTPV
AOWAS
D8T
ZZAVC
ID FETCH-LOGICAL-c506t-73813da7fea6ba7c18b7863c33c1e7ccbbf6b385e3c8a92538815604fa177bd33
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:32:39 EDT 2025
Mon Aug 25 03:32:41 EDT 2025
Thu Aug 21 18:38:36 EDT 2025
Thu Jul 10 22:15:04 EDT 2025
Mon Jul 21 06:04:55 EDT 2025
Tue Jul 01 02:13:37 EDT 2025
Thu Apr 24 23:04:55 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords telomerase
urothelial carcinoma
TERT
promoter methylation
urothelial cells
BCG
immunotherapy
promoter mutations
Language English
License Copyright © 2023 Liu, Li, Xia and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c506t-73813da7fea6ba7c18b7863c33c1e7ccbbf6b385e3c8a92538815604fa177bd33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Patrick Schmidt, National Center for Tumor Diseases (NCT), Germany; Karen Beemon, Johns Hopkins University, United States
Edited by: Jianzhong Ai, Sichuan University, China
ORCID: Dawei Xu, orcid.org/0000-0003-3141-4524
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.1071390
PMID 36713366
PQID 2771088143
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_9f303fe7e9104c4a8d3d6b366a41d43e
swepub_primary_oai_swepub_ki_se_448104
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9877314
proquest_miscellaneous_2771088143
pubmed_primary_36713366
crossref_primary_10_3389_fimmu_2022_1071390
crossref_citationtrail_10_3389_fimmu_2022_1071390
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-12
PublicationDateYYYYMMDD 2023-01-12
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-12
  day: 12
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Shay (B1) 2019; 20
Mancini (B55) 2018; 34
Descotes (B86) 2017; 117
Sheng (B116) 2018; 174
Yuan (B3) 2020; 20
Shain (B67) 2015; 373
Yuan (B58) 2019; 38
Nault (B66) 2014; 60
Hanahan (B5) 2011; 144
Barthel (B50) 2017; 49
Pan (B109) 2022; 13
Kurtis (B35) 2016; 21
van Kessel (B97) 2020; 204
Yuan (B63) 2022; 12
Dahmcke (B82) 2016; 70
Farwell (B20) 2000; 156
Leao (B107) 2019; 144
Hosen (B73) 2015; 137
Dumbovic (B81) 2021; 12
Hurst (B26) 2004; 23
Cuthill (B25) 1999; 26
Russo (B91) 2018; 4
Cheng (B37) 2022
Li (B15) 2015; 6
Critelli (B83) 2016; 7
Fu (B9) 2007; 28
Yuan (B54) 2020; 493
Roake (B11) 2020; 21
Zhang (B115) 2021; 598
Zachos (B94) 2009; 135
Rowland (B33) 2020; 14
Wang (B48) 2014; 5
Shay (B8) 1997; 33
Stasik (B92) 2019; 64
Marchese (B111) 2022; 236
Chapman (B23) 2008; 6
Smith (B118) 2018; 128
Maryoung (B75) 2017; 127
Glaser (B12) 2017; 14
Zhong (B99) 2015; 39
(B27) 2014; 507
de Kouchkovsky (B110) 2021; 9
Batista (B112) 2020; 21
Malhotra (B79) 2017; 4
Isharwal (B108) 2019; 5
Kiyono (B21) 1998; 396
Yuan (B4) 2019; 38
Georgopoulos (B13) 2011; 60
Kinde (B41) 2013; 73
Pritchard (B87) 2020; 38
Wang (B65) 2014; 120
Hayashi (B38) 2019; 110
Huang (B77) 2015; 4
Wu (B102) 2014; 65
Hosen (B89) 2020; 12
Chapman (B24) 2009; 48
Chapman (B14) 2006; 25
Neves (B104) 2002; 167
Ellingsen (B120) 2021; 12
Zhang (B30) 2017; 77
Alcorta (B18) 1996; 93
Hurst (B40) 2014; 65
Wan (B100) 2021; 12
Ouyang (B98) 2022; 14
Morozov (B44) 2021; 39
Xing (B56) 2022; 14
Guo (B59) 2020; 27
Vinci (B101) 2011; 29
Saretzki (B2) 2018; 90
Wang (B10) 2023; 17
Liu (B42) 2013; 12
Kim (B76) 2016; 14
Jansz (B114) 2021; 22
Stern (B53) 2017; 21
Ellingsen (B119) 2022; 10
Rheinwald (B22) 2002; 22
Wang (B46) 2014; 5
Allory (B43) 2014; 65
Wang (B70) 2018; 72
Starita (B74) 2018; 16
Soputro (B95) 2022; 3
Kakiuchi (B71) 2021; 21
Bodnar (B19) 1998; 279
Cheng (B36) 2016; 69
Yeager (B16) 1998; 12
Liu (B29) 2013; 32
Wang (B47) 2015; 20
van Kessel (B96) 2017; 197
Bell (B52) 2015; 348
Li (B51) 2020; 22
Mao (B113) 2022; 23
Hosen (B39) 2020
Yuan (B57) 2017; 8
Long (B62) 2020; 105
Dratwa (B6) 2020; 11
Ellingsen (B121) 2022; 20
Fang (B60) 2022; 41
Rachakonda (B45) 2013; 110
Ma (B61) 2021; 2021
Weyerer (B68) 2021; 12
Fujii (B28) 2021; 39
Hayashi (B49) 2021; 11
Belair (B17) 1997; 94
Liu (B72) 2014; 33
Bravaccini (B106) 2007; 178
Batista (B85) 2019; 10
Ott (B78) 2022; 14
Xu (B88) 2020; 10
Weikert (B103) 2005; 117
Horn (B32) 2013; 339
Hayashi (B90) 2020; 14
Chiappinelli (B117) 2015; 162
Roggisch (B34) 2020; 38
Agarwal (B64) 2021; 118
Penev (B80) 2021; 81
Cheng (B69) 2017; 71
Huang (B31) 2013; 339
Ou (B93) 2020; 9
Aamdal (B122) 2021; 12
Lewis (B7) 2016; 7
Xing (B84) 2021; 12
Lamarca (B105) 2012; 2012
References_xml – volume: 144
  year: 2019
  ident: B107
  article-title: Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.31935
– volume: 28
  year: 2007
  ident: B9
  article-title: Purification of human telomerase complexes identifies factors involved in telomerase biogenesis and telomere length regulation
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2007.09.023
– volume: 65
  year: 2014
  ident: B43
  article-title: Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2013.08.052
– volume: 21
  year: 2021
  ident: B71
  article-title: Clonal expansion in non-cancer tissues
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-021-00335-3
– volume: 14
  year: 2022
  ident: B78
  article-title: Differential DNA methylation of THOR and hTAPAS in the regulation of hTERT and the diagnosis of cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14184384
– volume: 197
  year: 2017
  ident: B96
  article-title: Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy
  publication-title: J Urol
  doi: 10.1016/j.juro.2016.09.118
– volume: 29
  year: 2011
  ident: B101
  article-title: Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2009.01.003
– volume: 12
  year: 1998
  ident: B16
  article-title: Overcoming cellular senescence in human cancer pathogenesis
  publication-title: Genes Dev
  doi: 10.1101/gad.12.2.163
– volume: 60
  year: 2014
  ident: B66
  article-title: Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis
  publication-title: Hepatology
  doi: 10.1002/hep.27372
– volume: 12
  year: 2021
  ident: B68
  article-title: TERT promoter mutation analysis of whole-organ mapping bladder cancers
  publication-title: Genes (Basel)
  doi: 10.3390/genes12020230
– volume: 14
  year: 2016
  ident: B76
  article-title: Regulation of the human telomerase gene TERT by telomere position effect-over long distances (TPE-OLD): Implications for aging and cancer
  publication-title: PloS Biol
  doi: 10.1371/journal.pbio.2000016
– volume: 127
  year: 2017
  ident: B75
  article-title: Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations
  publication-title: J Clin Inves
  doi: 10.1172/JCI91161
– volume: 73
  year: 2013
  ident: B41
  article-title: TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-2498
– volume: 71
  year: 2017
  ident: B69
  article-title: TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2016.12.008
– volume: 70
  year: 2016
  ident: B82
  article-title: A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2016.06.035
– volume: 12
  year: 2021
  ident: B84
  article-title: Regulatory region mutations of TERT, PLEKHS1 and GPR126 genes as urinary biomarkers in upper tract urothelial carcinomas
  publication-title: J Cancer
  doi: 10.7150/jca.56779
– volume: 12
  start-page: 3308
  year: 2021
  ident: B81
  article-title: Nuclear compartmentalization of TERT mRNA and TUG1 lncRNA is driven by intron retention
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-23221-w
– volume: 13
  year: 2022
  ident: B109
  article-title: Immune status for monitoring and treatment of bladder cancer
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.963877
– volume: 10
  year: 2020
  ident: B88
  article-title: A urine-based liquid biopsy method for detection of upper tract urinary carcinoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.597486
– volume: 23
  year: 2004
  ident: B26
  article-title: High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207260
– volume: 7
  year: 2016
  ident: B83
  article-title: Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11883
– volume: 5
  year: 2019
  ident: B108
  article-title: Prognostic value of TERT alterations, mutational and copy number alterations burden in urothelial carcinoma
  publication-title: Eur Urol Focus
  doi: 10.1016/j.euf.2017.07.004
– volume: 167
  year: 2002
  ident: B104
  article-title: Prospective evaluation of genetic abnormalities and telomerase expression in exfoliated urinary cells for bladder cancer detection
  publication-title: J Urol
  doi: 10.1016/S0022-5347(05)65281-0
– volume: 25
  year: 2006
  ident: B14
  article-title: Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209513
– volume: 39
  start-page: 793
  year: 2021
  ident: B28
  article-title: Molecular classification and diagnostics of upper urinary tract urothelial carcinoma
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2021.05.008
– volume: 69
  year: 2016
  ident: B36
  article-title: Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change
  publication-title: Histopathology
  doi: 10.1111/his.12920
– volume: 10
  year: 2022
  ident: B119
  article-title: Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2021-004345
– volume: 12
  year: 2020
  ident: B89
  article-title: Development of sensitive droplet digital PCR assays for detecting urinary TERT promoter mutations as non-invasive biomarkers for detection of urothelial cancer
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12123541
– volume: 507
  year: 2014
  ident: B27
  article-title: Comprehensive molecular characterization of urothelial bladder carcinoma
  publication-title: Nature
  doi: 10.1038/nature12965
– volume: 20
  year: 2020
  ident: B3
  article-title: Telomere- related markers for cancer
  publication-title: Curr Top Med Chem
  doi: 10.2174/1568026620666200106145340
– volume: 144
  year: 2011
  ident: B5
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 23
  year: 2022
  ident: B113
  article-title: TERT activates endogenous retroviruses to promote an immunosuppressive tumour microenvironment
  publication-title: EMBO Rep
  doi: 10.15252/embr.202152984
– volume: 105
  year: 2020
  ident: B62
  article-title: Lysine-specific demethylase 1 affects the progression of papillary thyroid carcinoma via HIF1alpha and microRNA-146a
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/clinem/dgaa182
– volume: 65
  year: 2014
  ident: B40
  article-title: Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2013.08.057
– volume: 22
  year: 2020
  ident: B51
  article-title: Programmable base editing of mutated TERT promoter inhibits brain tumour growth
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-020-0471-6
– volume: 39
  year: 2021
  ident: B44
  article-title: hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2021.01.022
– volume: 17
  year: 2023
  ident: B10
  article-title: Genomic, epigenomic and transcriptomic signatures for telomerase complex components: a pan-cancer analysis
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.13324
– volume: 21
  start-page: 7
  year: 2016
  ident: B35
  article-title: Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications
  publication-title: Ann Diagn Pathol
  doi: 10.1016/j.anndiagpath.2015.12.002
– volume: 8
  year: 2017
  ident: B57
  article-title: The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15498
– volume: 162
  year: 2015
  ident: B117
  article-title: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
  publication-title: Cell
  doi: 10.1016/j.cell.2015.07.011
– volume: 27
  year: 2020
  ident: B59
  article-title: GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer
  publication-title: Cell Death differentiation
  doi: 10.1038/s41418-019-0466-7
– volume: 48
  start-page: 694
  year: 2009
  ident: B24
  article-title: Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase-immortalized urothelial cells (TERT-NHUC)
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.20672
– volume: 72
  start-page: 795
  year: 2018
  ident: B70
  article-title: Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential
  publication-title: Histopathology
  doi: 10.1111/his.13441
– volume: 7
  year: 2016
  ident: B7
  article-title: Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms
  publication-title: Front Genet
  doi: 10.3389/fgene.2016.00083
– volume: 156
  year: 2000
  ident: B20
  article-title: Genetic and epigenetic changes in human epithelial cells immortalized by telomerase
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)65025-0
– volume: 33
  year: 2014
  ident: B72
  article-title: The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas
  publication-title: Oncogene
  doi: 10.1038/onc.2013.446
– volume: 5
  year: 2014
  ident: B48
  article-title: TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1829
– volume: 204
  year: 2020
  ident: B97
  article-title: A urine based genomic assay to triage patients with hematuria for cystoscopy
  publication-title: J Urol
  doi: 10.1097/JU.0000000000000786
– year: 2022
  ident: B37
  article-title: Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2022.06.005
– volume: 4
  year: 2018
  ident: B91
  article-title: Toward personalised liquid biopsies for urothelial carcinoma: Characterisation of ddPCR and urinary cfDNA for the detection of the TERT 228 G>A/T mutation
  publication-title: Bladder Cancer
  doi: 10.3233/BLC-170152
– volume: 6
  year: 2008
  ident: B23
  article-title: Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells
  publication-title: Mol Cancer Res
  doi: 10.1158/1541-7786.MCR-07-2168
– volume: 14
  year: 2017
  ident: B12
  article-title: The evolving genomic landscape of urothelial carcinoma
  publication-title: Nat Rev Urol
  doi: 10.1038/nrurol.2017.11
– volume: 16
  start-page: 77
  year: 2018
  ident: B74
  article-title: Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
  publication-title: J Transl Med
  doi: 10.1186/s12967-018-1456-0
– volume: 128
  year: 2018
  ident: B118
  article-title: Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
  publication-title: J Clin Inves
  doi: 10.1172/JCI121476
– volume: 120
  year: 2014
  ident: B65
  article-title: TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA
  publication-title: Cancer
  doi: 10.1002/cncr.28800
– volume: 348
  year: 2015
  ident: B52
  article-title: Cancer. the transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
  publication-title: Science
  doi: 10.1126/science.aab0015
– volume: 11
  year: 2020
  ident: B6
  article-title: TERT-regulation and roles in cancer formation
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.589929
– volume: 137
  year: 2015
  ident: B73
  article-title: Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.29526
– volume: 339
  year: 2013
  ident: B31
  article-title: Highly recurrent TERT promoter mutations in human melanoma
  publication-title: Science
  doi: 10.1126/science.1229259
– volume: 93
  year: 1996
  ident: B18
  article-title: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.93.24.13742
– volume: 12
  year: 2021
  ident: B122
  article-title: Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma - five-year follow up of a phase I/IIa trial
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.663865
– volume: 110
  year: 2019
  ident: B38
  article-title: Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma
  publication-title: Cancer Sci
  doi: 10.1111/cas.14000
– volume: 4
  year: 2015
  ident: B77
  article-title: TERT promoter mutations and monoallelic activation of TERT in cancer
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2015.39
– volume: 493
  start-page: 1
  year: 2020
  ident: B54
  article-title: TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2020.07.003
– volume: 34
  start-page: 513
  year: 2018
  ident: B55
  article-title: Disruption of the beta1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2018.08.003
– volume: 22
  start-page: 147
  year: 2021
  ident: B114
  article-title: Endogenous retroviruses in the origins and treatment of cancer
  publication-title: Genome Biol
  doi: 10.1186/s13059-021-02357-4
– volume: 38
  year: 2020
  ident: B87
  article-title: Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2020.05.012
– volume: 22
  year: 2002
  ident: B22
  article-title: A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.22.14.5157-5172.2002
– volume: 41
  start-page: 173
  year: 2022
  ident: B60
  article-title: GABPA-activated TGFBR2 transcription inhibits aggressiveness but is epigenetically erased by oncometabolites in renal cell carcinoma
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-022-02382-6
– volume: 9
  year: 2021
  ident: B110
  article-title: TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-002127
– volume: 174
  start-page: 549
  year: 2018
  ident: B116
  article-title: LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade
  publication-title: Cell
  doi: 10.1016/j.cell.2018.05.052
– volume: 279
  year: 1998
  ident: B19
  article-title: Extension of life-span by introduction of telomerase into normal human cells
  publication-title: Science
  doi: 10.1126/science.279.5349.349
– volume: 38
  year: 2020
  ident: B34
  article-title: Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2019.08.007
– volume: 236
  start-page: 153983
  year: 2022
  ident: B111
  article-title: A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2022.153983
– volume: 3
  year: 2022
  ident: B95
  article-title: Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis
  publication-title: BJUI Compass
  doi: 10.1002/bco2.147
– volume: 6
  year: 2015
  ident: B15
  article-title: The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4295
– volume: 14
  year: 2020
  ident: B90
  article-title: TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12746
– volume: 20
  year: 2015
  ident: B47
  article-title: TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in han Chinese patients with urothelial bladder cancer
  publication-title: oncol
  doi: 10.1634/theoncologist.2014-0391
– volume: 598
  year: 2021
  ident: B115
  article-title: KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
  publication-title: Nature
  doi: 10.1038/s41586-021-03994-2
– volume: 117
  year: 2017
  ident: B86
  article-title: Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2017.210
– volume: 38
  year: 2019
  ident: B58
  article-title: GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0483-x
– volume: 20
  start-page: 419
  year: 2022
  ident: B121
  article-title: Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
  publication-title: J Transl Med
  doi: 10.1186/s12967-022-03624-z
– volume: 12
  year: 2021
  ident: B120
  article-title: Telomerase as a target for therapeutic cancer vaccines and considerations for optimizing their clinical potential
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.682492
– volume: 2012
  start-page: 693631
  year: 2012
  ident: B105
  article-title: Urine telomerase for diagnosis and surveillance of bladder cancer
  publication-title: Adv Urol
  doi: 10.1155/2012/693631
– volume: 21
  year: 2017
  ident: B53
  article-title: Allele-specific DNA methylation and its interplay with repressive histone marks at promoter-mutant TERT genes
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.12.001
– volume: 4
  year: 2017
  ident: B79
  article-title: A novel long non-coding RNA in the hTERT promoter region regulates hTERT expression
  publication-title: Noncoding RNA
  doi: 10.3390/ncrna4010001
– volume: 11
  year: 2021
  ident: B49
  article-title: Clinical application of TERT promoter mutations in urothelial carcinoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.705440
– volume: 94
  year: 1997
  ident: B17
  article-title: Telomerase activity: a biomarker of cell proliferation, not malignant transformation
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.94.25.13677
– volume: 9
  start-page: 4
  year: 2020
  ident: B93
  article-title: Detection of bladder cancer using urinary cell-free DNA and cellular DNA
  publication-title: Clin Transl Med
  doi: 10.1186/s40169-020-0257-2
– volume: 12
  year: 2021
  ident: B100
  article-title: The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer
  publication-title: Bioengineered
  doi: 10.1080/21655979.2021.1915725
– volume: 12
  year: 2022
  ident: B63
  article-title: Thyroid carcinoma-featured telomerase activation and telomere maintenance: Biology and translational/clinical significance
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.1111
– volume: 26
  year: 1999
  ident: B25
  article-title: Dominant genetic alterations in immortalization: role for 20q gain
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1
– volume: 65
  year: 2014
  ident: B102
  article-title: Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2013.10.038
– volume: 117
  year: 2005
  ident: B103
  article-title: Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21168
– volume: 110
  year: 2013
  ident: B45
  article-title: TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.1310522110
– volume: 14
  year: 2022
  ident: B56
  article-title: Downregulation and hypermethylation of GABPB1 is associated with aggressive thyroid cancer features
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14061385
– volume: 135
  year: 2009
  ident: B94
  article-title: Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-009-0557-9
– volume: 38
  year: 2019
  ident: B4
  article-title: Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0872-9
– volume: 60
  year: 2011
  ident: B13
  article-title: Immortalisation of normal human urothelial cells compromises differentiation capacity
  publication-title: Eur urol
  doi: 10.1016/j.eururo.2011.02.022
– volume: 33
  year: 1997
  ident: B8
  article-title: A survey of telomerase activity in human cancer
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(97)00062-2
– volume: 5
  year: 2014
  ident: B46
  article-title: TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2660
– volume: 14
  year: 2020
  ident: B33
  article-title: Allele-specific proximal promoter hypomethylation of the telomerase reverse transcriptase gene (TERT) associates with TERT expression in multiple cancers
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12786
– volume: 118
  year: 2021
  ident: B64
  article-title: TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.2102423118
– volume: 20
  start-page: 299
  year: 2019
  ident: B1
  article-title: Telomeres and telomerase: three decades of progress
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-019-0099-1
– volume: 21
  year: 2020
  ident: B112
  article-title: TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21030947
– volume: 64
  year: 2019
  ident: B92
  article-title: Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer
  publication-title: Clin Biochem
  doi: 10.1016/j.clinbiochem.2018.11.009
– volume: 21
  year: 2020
  ident: B11
  article-title: Regulation of human telomerase in homeostasis and disease.
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1002/1878-0261.13324
– volume: 373
  year: 2015
  ident: B67
  article-title: The genetic evolution of melanoma from precursor lesions
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa1502583
– volume: 14
  year: 2022
  ident: B98
  article-title: Urine cellular DNA point mutation and methylation for identifying upper tract urinary carcinoma
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14143537
– volume: 396
  year: 1998
  ident: B21
  article-title: Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
  publication-title: Nature
  doi: 10.1038/23962
– volume: 81
  start-page: 2349
  year: 2021
  ident: B80
  article-title: Alternative splicing is a developmental switch for hTERT expression
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.03.033
– volume: 90
  start-page: 221
  year: 2018
  ident: B2
  article-title: Telomeres, telomerase and ageing
  publication-title: Subcell Biochem
  doi: 10.1007/978-981-13-2835-0_9
– volume: 178
  start-page: 57
  year: 2007
  ident: B106
  article-title: Urine telomerase activity for the detection of bladder cancer in females
  publication-title: J Urol
  doi: 10.1016/j.juro.2007.03.025
– volume: 2021
  start-page: 5552614
  year: 2021
  ident: B61
  article-title: GABPA expression in endometrial carcinoma: A prognostic marker
  publication-title: Dis Markers
  doi: 10.1155/2021/5552614
– volume: 12
  year: 2013
  ident: B42
  article-title: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma
  publication-title: Cell Cycle
  doi: 10.4161/cc.24662
– volume: 339
  year: 2013
  ident: B32
  article-title: TERT promoter mutations in familial and sporadic melanoma
  publication-title: Science
  doi: 10.1126/science.1230062
– volume: 49
  year: 2017
  ident: B50
  article-title: Systematic analysis of telomere length and somatic alterations in 31 cancer types
  publication-title: Nat Genet
  doi: 10.1038/ng.3781
– start-page: 102643
  year: 2020
  ident: B39
  article-title: Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the golestan cohort study
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.102643
– volume: 10
  year: 2019
  ident: B85
  article-title: Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-Muscle-Invasive bladder cancer in a comprehensive multicenter study
  publication-title: Front Genet
  doi: 10.3389/fgene.2019.01237
– volume: 39
  year: 2015
  ident: B99
  article-title: Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000305
– volume: 32
  year: 2013
  ident: B29
  article-title: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells
  publication-title: Oncogene
  doi: 10.1038/onc.2012.441
– volume: 77
  year: 2017
  ident: B30
  article-title: WNT/beta-catenin directs self-renewal symmetric cell division of hTERT(high) prostate cancer stem cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-1887
SSID ssj0000493335
Score 2.4093244
SecondaryResourceType review_article
Snippet Telomerase, an RNA-dependent DNA polymerase synthesizing telomeric TTAGGG sequences, is primarily silent in normal human urothelial cells (NHUCs), but widely...
SourceID doaj
swepub
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1071390
SubjectTerms BCG
Carcinoma, Transitional Cell - genetics
Clinical Relevance
Humans
Immunology
immunotherapy
Methylation
Mutation
promoter methylation
promoter mutations
telomerase
Telomerase - genetics
Telomerase - metabolism
TERT
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - pathology
SummonAdditionalLinks – databaseName: Open Access资源_DOAJ
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQSitxQbwJj5WREBcUbRM7dsKNXbFaceC0K-3N8mMsCm26apvD_gl-MzN2WjUCwYVbmzqp7fkyj-SbGcbe1TEqV0FXhlapUgZpS9dCLAOgeQgNgAqJIPtVXV7LLzfNzUGrL-KE5fLAeeNOu4hKNoIGtGvSS9sGEZQTSllZBSmAtC_avINg6nv2e4UQTc6SwSisO43z5XLAeLCuMWDFyIyU8IElSgX7_-Rl_k6WnJQUTWbo4iF7MPqP_FOe9yN2D_rH7Dh3lLx7wn6id3rFbxPHDtZ8OeQ37Rtu-8CpW_Rd5r5x9FX5FhYreia1AU7pDfnhLJ_3fFhTXtYCock99RrqiUT0kaNCxGtQqnCq7owjNxTa54vvUiw5MUKIf0RwesquLz5fnV-WY8uF0jcztS01SkgEqyNY5az2Vet0q4QXwlegvXcORSvaBoRvbVejtqRqMzMZbaW1C0I8Y0f9qocXjKMjU4NvopRWyZmVDlTnOwFV0I3GLwWrdttv_FiPnNpiLAzGJSQyk0RmSGRmFFnBPuzPuc3VOP46-oykuh9JlbTTAcSXGfFl_oWvgr3dYcLgnUevU2wPq2Fjao3eGa5fioI9zxjZ_5VQFPwrXKSeoGcyl-kv_fxbqu7dtVqLShbsfcbZ5JTx0A_8BAYja5zzy_-xylfsPu4cMevKqn7NjrbrAd6gt7V1J-nG-gUyoy3w
  priority: 102
  providerName: Directory of Open Access Journals
Title TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: New mechanistic insights and clinical significance
URI https://www.ncbi.nlm.nih.gov/pubmed/36713366
https://www.proquest.com/docview/2771088143
https://pubmed.ncbi.nlm.nih.gov/PMC9877314
http://kipublications.ki.se/Default.aspx?queryparsed=id:151738428
https://doaj.org/article/9f303fe7e9104c4a8d3d6b366a41d43e
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA7LirIv4t16WSKIL1KdNmnSCiIqrougTzswbyVNTnV0prO2U3D-hL_Zc5J2pLjry9Bpk15yTnq-Lz0Xxp6mda2qBIrY5UrF0kkTVznUsQM0Dy4DUM47yH5Rp3P5aZEtDthY7mgYwO5Cakf1pObt6sWvn7s3OOFfE-NEe_uyXq7XPVK9NEUuiqSrQAp_BS2TpooGnwe4_z2gYSFEFmJnLul6xK4JRczN5038a6p8Rv-LYOi_3pSTnKPeTp3cYNcHgMnfBo24yQ6gucWuhpKTu9vsN8LXM37unfCg5es-fIrvuGkcp3LSu-AcxxHM8i2sNrRo1QGn-IewesuXDe9bCtxaoe5yS8WIGvIyesXxjYnnoFhin_4ZW3bE_cPJxxhMTi4j5KBE-naHzU8-nL0_jYeaDLHNZmobaxShcEbXYFRltE3ySudKWCFsAtraqkLZizwDYXNTpPg6pXQ0M1mbROvKCXGXHTabBu4zjkgnBZvVUholZ0ZWoApbCEiczjT-iVgyDn9ph4TlVDdjVSJxIemVXnolSa8cpBex5_s-5yFdx39bvyOp7ltSqm2_Y9N-LYeZWxY1WvkaNCCwklaa3AmHj6iUkYmTAiL2ZNSJEqcmfW8xDWz6rkw1wjd8fikidi_oyP5So45FTE-0Z3Iv0yPN8ptP_13kWotERuxZ0LNJl2HXD9yCEqk33vODSy_-kB3hcJA_XZykj9jhtu3hMWKsbXXs1ybw9-MiOfaT6A9zZisn
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TERT+promoter+mutations+and+methylation+for+telomerase+activation+in+urothelial+carcinomas%3A+New+mechanistic+insights+and+clinical+significance&rft.jtitle=Frontiers+in+immunology&rft.au=Liu%2C+Tiantian&rft.au=Li%2C+Shihong&rft.au=Xia%2C+Chuanyou&rft.au=Xu%2C+Dawei&rft.date=2023-01-12&rft.eissn=1664-3224&rft.volume=13&rft.spage=1071390&rft_id=info:doi/10.3389%2Ffimmu.2022.1071390&rft_id=info%3Apmid%2F36713366&rft.externalDocID=36713366
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon